search
Back to results

Triple Target Treatment (3T) Which Combines Stimulation With Amplitude Modulated Middle Frequency (AM-MF), Electromyography (EMG)-Triggered Stimulation and EMG-Biofeedback Compared With EMG-Biofeedback in Anal Incontinence (3T-AI)

Primary Purpose

Fecal Incontinence

Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation
EMG-biofeedback alone
Sponsored by
University of Giessen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fecal Incontinence focused on measuring Exercise Therapy, Biofeedback (Psychology), Adult, Fecal Incontinence/*therapy, EMG - Biofeedback, EMG - Triggered Stimulation, Augmented biofeedback

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All Patients with fecal incontinence I-III.

Exclusion Criteria:

  • All Patients with CID´s
  • Definite or possible pregnancy

Sites / Locations

  • University of Gießen, Dept. of General Surgery

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

EMG-biofeedback plus EMG-triggered AM-MF-stimulation

EMG-biofeedback alone

Arm Description

Outcomes

Primary Outcome Measures

Cleveland Clinic Incontinence Score (CCS) in its validated German form after nine months, compared to baseline
Validated new St. Mark's incontinence score (Vaizey score) in its adapted German form after nine months, compared to baseline.

Secondary Outcome Measures

CCS score after six or three months, compared to baseline
Adapted Vaizey score after six or three months compared to baseline
Quality of life according to the Fecal Incontinence Quality of Life Scale (FIQoL) in its validated German form after nine months compared to baseline, as well as between the two treatment groups over the course of time as compared to baseline
Track record of the treatment: 1. Continent, 2. Grade improvement (grade II or III to grade I), 3. Frequency improvement: (same grade, >= 2 points improvement in CCS), 4. no improvement, or deterioration, 5. early dropouts.
Use of stool regulating medication. Specifically, if biofeedback and 3T increase continence, the use of any stool regulating medication (Fleawort seeds, Loperamide, teas, etc.) should decrease in the course of the trial.

Full Information

First Posted
September 4, 2007
Last Updated
February 17, 2009
Sponsor
University of Giessen
search

1. Study Identification

Unique Protocol Identification Number
NCT00525291
Brief Title
Triple Target Treatment (3T) Which Combines Stimulation With Amplitude Modulated Middle Frequency (AM-MF), Electromyography (EMG)-Triggered Stimulation and EMG-Biofeedback Compared With EMG-Biofeedback in Anal Incontinence
Acronym
3T-AI
Official Title
Prospective, Randomized Multicenter Study to Assess the Outcome of Conservative 3T Treatment With EMG-Biofeedback
Study Type
Interventional

2. Study Status

Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
December 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Giessen

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The efficacy of biofeedback and/or low frequency electrical stimulation for the treatment of anal incontinence has not been proven. First, large well-designed clinical trials are missing. Second, only few patients reach therapeutically relevant intensities with low frequency stimulation. In this study, a novel therapeutic concept, termed triple target treatment (3T) was evaluated. 3T combines stimulation with amplitude modulated middle frequency (AM-MF), electromyography (EMG)-triggered stimulation and EMG-biofeedback. 3T was compared with EMG-biofeedback alone after a nine month treatment period. Methods In this parallel-group randomised multicenter study with blinded observer we enrolled 158 patients with anal incontinence. Primary endpoints were changes from baseline to nine months in the Cleveland Clinic Score (CCS) and the St. Mark's score (Vaizey score).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fecal Incontinence
Keywords
Exercise Therapy, Biofeedback (Psychology), Adult, Fecal Incontinence/*therapy, EMG - Biofeedback, EMG - Triggered Stimulation, Augmented biofeedback

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
158 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EMG-biofeedback plus EMG-triggered AM-MF-stimulation
Arm Type
Experimental
Arm Title
EMG-biofeedback alone
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation
Intervention Description
In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
Intervention Type
Device
Intervention Name(s)
EMG-biofeedback alone
Intervention Description
In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
Primary Outcome Measure Information:
Title
Cleveland Clinic Incontinence Score (CCS) in its validated German form after nine months, compared to baseline
Time Frame
9 months after randomization
Title
Validated new St. Mark's incontinence score (Vaizey score) in its adapted German form after nine months, compared to baseline.
Time Frame
9 months after randomization
Secondary Outcome Measure Information:
Title
CCS score after six or three months, compared to baseline
Time Frame
3 months, 6 months after randomization
Title
Adapted Vaizey score after six or three months compared to baseline
Time Frame
3 months, 6 months
Title
Quality of life according to the Fecal Incontinence Quality of Life Scale (FIQoL) in its validated German form after nine months compared to baseline, as well as between the two treatment groups over the course of time as compared to baseline
Time Frame
9 months after randomization
Title
Track record of the treatment: 1. Continent, 2. Grade improvement (grade II or III to grade I), 3. Frequency improvement: (same grade, >= 2 points improvement in CCS), 4. no improvement, or deterioration, 5. early dropouts.
Time Frame
9 months after randomization
Title
Use of stool regulating medication. Specifically, if biofeedback and 3T increase continence, the use of any stool regulating medication (Fleawort seeds, Loperamide, teas, etc.) should decrease in the course of the trial.
Time Frame
9 months after randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All Patients with fecal incontinence I-III. Exclusion Criteria: All Patients with CID´s Definite or possible pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thilo Schwandner, Dr.
Organizational Affiliation
University of Giessen
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Gießen, Dept. of General Surgery
City
Gießen
State/Province
Hesse
ZIP/Postal Code
35385
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
21968596
Citation
Schwandner T, Heimerl T, Konig IR, Kierer W, Roblick M, Bouchard R, Unglaube T, Holch P, Kolbert G, Padberg W, Ziegler A. [3T-AI: a new treatment algorithm for anal incontinence with a higher evidence level]. Zentralbl Chir. 2012 Aug;137(4):345-51. doi: 10.1055/s-0031-1271468. Epub 2011 Sep 27. German.
Results Reference
derived
PubMed Identifier
20551752
Citation
Schwandner T, Konig IR, Heimerl T, Kierer W, Roblick M, Bouchard R, Unglaube T, Holch P, Ziegler A, Kolbert G. Triple target treatment (3T) is more effective than biofeedback alone for anal incontinence: the 3T-AI study. Dis Colon Rectum. 2010 Jul;53(7):1007-16. doi: 10.1007/DCR.0b013e3181db7738. Erratum In: Dis Colon Rectum. 2011 Nov;54(11):1461.
Results Reference
derived

Learn more about this trial

Triple Target Treatment (3T) Which Combines Stimulation With Amplitude Modulated Middle Frequency (AM-MF), Electromyography (EMG)-Triggered Stimulation and EMG-Biofeedback Compared With EMG-Biofeedback in Anal Incontinence

We'll reach out to this number within 24 hrs